---
document_datetime: 2025-12-09 23:31:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo.html
document_name: briviact-italy-nubriveo.html
version: success
processing_time: 0.1264788
conversion_datetime: 2025-12-27 16:03:02.427058
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Briviact (in Italy: Nubriveo)

[RSS](/en/individual-human-medicine.xml/66901)

##### Authorised

This medicine is authorised for use in the European Union

brivaracetam Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Briviact (in Italy: Nubriveo)](#news-on)
- [More information on Briviact (in Italy: Nubriveo)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Briviact is an epilepsy medicine used as an add-on to other epilepsy medicines to treat partial-onset seizures (epileptic fits starting in one specific part of the brain). It can be used in patients from the age of 2 years with partial-onset seizures with or without secondary generalisation (where the abnormal electrical activity spreads through the brain). Briviact contains the active substance brivaracetam.

Expand section

Collapse section

## How is Briviact used?

Briviact can only be obtained with a prescription. The medicine is available as tablets, an oral solution (a liquid taken by mouth) and a solution for injection or infusion (drip) into a vein, which is used when the medicine cannot be given by mouth.

The recommended starting dose depends on the patient's body weight. After starting treatment, the dose can be adjusted according to the patient's needs.

For more information about using Briviact, see the package leaflet or contact a doctor or pharmacist.

## How does Briviact work?

Epilepsy is caused by excessive electrical activity in certain areas of the brain. The exact way in which brivaracetam, the active substance in Briviact, works is not clear, but it attaches to a protein called synaptic vesicle protein 2A, which is involved in the release of chemical messengers from nerve cells. This helps Briviact to stabilise electrical activity in the brain and prevent seizures.

## What benefits of Briviact have been shown in studies?

Briviact is more effective than placebo (a dummy treatment) at reducing seizures. This was shown in three main studies involving a total of 1,558 patients aged 16 years and above. Either Briviact or placebo was added to patients' usual epilepsy treatment. Taking the studies together, the frequency of seizures was at least halved in 34 to 38% of those adding Briviact at doses from 25 to 100 mg twice a day. This compares with 20% in those adding placebo.

Supportive studies showed that the doses recommended for children produced similar amounts of the medicine in the body to those seen with recommended doses in adults. Therefore Briviact is expected to work in children in the same way.

## What are the risks associated with Briviact?

The most common side effects with Briviact (which may affect more than 1 in 10 people) are somnolence (sleepiness) and dizziness. For the full list of side effects of Briviact, see the package leaflet.

## Why is Briviact authorised in the EU?

The European Medicines Agency decided that Briviact's benefits are greater than its risks and it can be authorised for use in the EU.

Clinical studies have shown add-on treatment with Briviact to be more effective than placebo for controlling partial-onset seizures in adults and children from 2 years of age. Most side effects of Briviact were of mild or moderate severity and were considered manageable.

## What measures are being taken to ensure the safe and effective use of Briviact?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Briviact have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Briviact are continuously monitored. Side effects reported with Briviact are carefully evaluated and any necessary action taken to protect patients.

## Other information about Briviact

Briviact received a marketing authorisation valid throughout the EU on 14 January 2016.

Briviact : EPAR - Medicine overview

Reference Number: EMA/70742/2022

English (EN) (117.53 KB - PDF)

**First published:** 25/01/2016

**Last updated:** 17/03/2022

[View](/en/documents/overview/briviact-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-104)

български (BG) (140.43 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/bg/documents/overview/briviact-epar-medicine-overview_bg.pdf)

español (ES) (115.45 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/es/documents/overview/briviact-epar-medicine-overview_es.pdf)

čeština (CS) (137.36 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/cs/documents/overview/briviact-epar-medicine-overview_cs.pdf)

dansk (DA) (113.82 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/da/documents/overview/briviact-epar-medicine-overview_da.pdf)

Deutsch (DE) (117.22 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/de/documents/overview/briviact-epar-medicine-overview_de.pdf)

eesti keel (ET) (103.41 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/et/documents/overview/briviact-epar-medicine-overview_et.pdf)

ελληνικά (EL) (141.51 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/el/documents/overview/briviact-epar-medicine-overview_el.pdf)

français (FR) (117.57 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/fr/documents/overview/briviact-epar-medicine-overview_fr.pdf)

hrvatski (HR) (134.55 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/hr/documents/overview/briviact-epar-medicine-overview_hr.pdf)

italiano (IT) (113.96 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/it/documents/overview/briviact-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (152.19 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/lv/documents/overview/briviact-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (136.08 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/lt/documents/overview/briviact-epar-medicine-overview_lt.pdf)

magyar (HU) (134.58 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/hu/documents/overview/briviact-epar-medicine-overview_hu.pdf)

Malti (MT) (137.83 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/mt/documents/overview/briviact-epar-medicine-overview_mt.pdf)

Nederlands (NL) (115.2 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/nl/documents/overview/briviact-epar-medicine-overview_nl.pdf)

polski (PL) (139.34 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/pl/documents/overview/briviact-epar-medicine-overview_pl.pdf)

português (PT) (116.43 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/pt/documents/overview/briviact-epar-medicine-overview_pt.pdf)

română (RO) (134.86 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/ro/documents/overview/briviact-epar-medicine-overview_ro.pdf)

slovenčina (SK) (136.95 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/sk/documents/overview/briviact-epar-medicine-overview_sk.pdf)

slovenščina (SL) (134.04 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/sl/documents/overview/briviact-epar-medicine-overview_sl.pdf)

Suomi (FI) (113.02 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/fi/documents/overview/briviact-epar-medicine-overview_fi.pdf)

svenska (SV) (113.66 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

17/03/2022

[View](/sv/documents/overview/briviact-epar-medicine-overview_sv.pdf)

Briviact : EPAR - Risk-management-plan summary

English (EN) (2.83 MB - PDF)

**First published:** 25/01/2016

**Last updated:** 17/04/2024

[View](/en/documents/rmp-summary/briviact-epar-risk-management-plan-summary_en.pdf)

## Product information

Briviact : EPAR - Product Information

English (EN) (1.03 MB - PDF)

**First published:** 25/01/2016

**Last updated:** 19/05/2025

[View](/en/documents/product-information/briviact-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-412)

български (BG) (1.01 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/bg/documents/product-information/briviact-epar-product-information_bg.pdf)

español (ES) (983.12 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/es/documents/product-information/briviact-epar-product-information_es.pdf)

čeština (CS) (954.32 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/cs/documents/product-information/briviact-epar-product-information_cs.pdf)

dansk (DA) (872.86 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/da/documents/product-information/briviact-epar-product-information_da.pdf)

Deutsch (DE) (1009.56 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/de/documents/product-information/briviact-epar-product-information_de.pdf)

eesti keel (ET) (924.43 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/et/documents/product-information/briviact-epar-product-information_et.pdf)

ελληνικά (EL) (977.75 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/el/documents/product-information/briviact-epar-product-information_el.pdf)

français (FR) (965.94 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/fr/documents/product-information/briviact-epar-product-information_fr.pdf)

hrvatski (HR) (1.08 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/hr/documents/product-information/briviact-epar-product-information_hr.pdf)

íslenska (IS) (974.95 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/is/documents/product-information/briviact-epar-product-information_is.pdf)

italiano (IT) (1.2 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/it/documents/product-information/briviact-epar-product-information_it.pdf)

latviešu valoda (LV) (1.1 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/lv/documents/product-information/briviact-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.02 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/lt/documents/product-information/briviact-epar-product-information_lt.pdf)

magyar (HU) (1.11 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/hu/documents/product-information/briviact-epar-product-information_hu.pdf)

Malti (MT) (982.53 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/mt/documents/product-information/briviact-epar-product-information_mt.pdf)

Nederlands (NL) (1.03 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/nl/documents/product-information/briviact-epar-product-information_nl.pdf)

norsk (NO) (897.57 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/no/documents/product-information/briviact-epar-product-information_no.pdf)

polski (PL) (1.09 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/pl/documents/product-information/briviact-epar-product-information_pl.pdf)

português (PT) (1001.87 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/pt/documents/product-information/briviact-epar-product-information_pt.pdf)

română (RO) (1.01 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/ro/documents/product-information/briviact-epar-product-information_ro.pdf)

slovenčina (SK) (1001.71 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/sk/documents/product-information/briviact-epar-product-information_sk.pdf)

slovenščina (SL) (919.71 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/sl/documents/product-information/briviact-epar-product-information_sl.pdf)

Suomi (FI) (1.09 MB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/fi/documents/product-information/briviact-epar-product-information_fi.pdf)

svenska (SV) (990.69 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

19/05/2025

[View](/sv/documents/product-information/briviact-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000266248 19/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Briviact : EPAR - All Authorised presentations

English (EN) (87.18 KB - PDF)

**First published:** 25/01/2016

**Last updated:** 22/10/2020

[View](/en/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-599)

български (BG) (138.57 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/bg/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_bg.pdf)

español (ES) (128.95 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/es/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_es.pdf)

čeština (CS) (131.42 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/cs/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (123.88 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/da/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (125.66 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/de/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (121.46 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/et/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (144.1 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/el/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_el.pdf)

français (FR) (126.63 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/fr/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (128.15 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/hr/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (91.52 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/is/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_is.pdf)

italiano (IT) (78.44 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/it/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (90.17 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/lv/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (111.09 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/lt/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (132.73 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/hu/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (133.57 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/mt/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (125.33 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/nl/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (89.73 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/no/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_no.pdf)

polski (PL) (132.97 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/pl/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_pl.pdf)

português (PT) (102.23 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/pt/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_pt.pdf)

română (RO) (133.25 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/ro/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (128.82 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/sk/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (90.67 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/sl/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (122.79 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/fi/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (122.67 KB - PDF)

**First published:**

25/01/2016

**Last updated:**

22/10/2020

[View](/sv/documents/all-authorised-presentations/briviact-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Briviact (in Italy: Nubriveo) Active substance Brivaracetam International non-proprietary name (INN) or common name brivaracetam Therapeutic area (MeSH) Epilepsy Anatomical therapeutic chemical (ATC) code N03AX23

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

## Authorisation details

EMA product number EMEA/H/C/003898 Marketing authorisation holder

UCB Pharma SA

Allée de la Recherche 60

Marketing authorisation issued 13/01/2016 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Briviact : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.93 KB - PDF)

**First published:** 19/05/2025

[View](/en/documents/procedural-steps-after/briviact-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Briviact : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (206.19 KB - PDF)

**First published:** 19/05/2016

**Last updated:** 19/05/2025

[View](/en/documents/procedural-steps-after/briviact-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Briviact-PAM-0000295195 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2419974

English (EN) (738.63 KB - PDF)

**First published:** 01/12/2025

[View](/en/documents/variation-report/briviact-pam-0000295195-epar-assessment-report_en.pdf)

Briviact-PAM-0000278054 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2194634

English (EN) (334.88 KB - PDF)

**First published:** 20/10/2025

[View](/en/documents/variation-report/briviact-pam-0000278054-epar-assessment-report_en.pdf)

Briviact-H-C-PSUSA-00010447-202401 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/CHMP/560256/2024

English (EN) (159.98 KB - PDF)

**First published:** 03/12/2024

[View](/en/documents/scientific-conclusion/briviact-h-c-psusa-00010447-202401-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Briviact-H-C-3898-P46-012 : EPAR - Assessment Report

Adopted

Reference Number: EMA/110857/2023

English (EN) (431.73 KB - PDF)

**First published:** 08/03/2023

[View](/en/documents/variation-report/briviact-h-c-3898-p46-012-epar-assessment-report_en.pdf)

Briviact-H-C-3898-P46-011 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/777450/2022

English (EN) (632.1 KB - PDF)

**First published:** 10/11/2022

[View](/en/documents/variation-report/briviact-h-c-3898-p46-011-epar-assessment-report_en.pdf)

Briviact-H-C-3898-P46-010 : EPAR - Assessment Report

Adopted

Reference Number: EMA/798155/2022

English (EN) (1.14 MB - PDF)

**First published:** 11/10/2022

[View](/en/documents/variation-report/briviact-h-c-3898-p46-010-epar-assessment-report_en.pdf)

Briviact-H-C-3898-P46-009 : EPAR - Assessment Report

Adopted

Reference Number: EMA/734633/2022

English (EN) (1.16 MB - PDF)

**First published:** 05/10/2022

[View](/en/documents/variation-report/briviact-h-c-3898-p46-009-epar-assessment-report_en.pdf)

Briviact-H-C-3898-II-0032-G : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/99325/2022

English (EN) (4.08 MB - PDF)

**First published:** 17/03/2022

[View](/en/documents/variation-report/briviact-h-c-3898-ii-0032-g-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of opinion for Briviact (II-32-G)

Adopted

Reference Number: EMA/CHMP/37228/2022

English (EN) (124.04 KB - PDF)

**First published:** 28/01/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-briviact-ii-32-g_en.pdf)

Briviact-H-C-3898-P46-008 : EPAR - Assessment Report

Adopted

Reference Number: EMA/393940/2021

English (EN) (2.83 MB - PDF)

**First published:** 12/07/2021

[View](/en/documents/variation-report/briviact-h-c-3898-p46-008-epar-assessment-report_en.pdf)

Briviact-H-C-3898-P46-007 : EPAR - Assessment Report

Adopted

Reference Number: EMA/165350/2021

English (EN) (331.79 KB - PDF)

**First published:** 23/03/2021

[View](/en/documents/variation-report/briviact-h-c-3898-p46-007-epar-assessment-report_en.pdf)

Briviact-H-C-PSUSA-00010447-202001 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/654572/2020

English (EN) (131.65 KB - PDF)

**First published:** 07/12/2020

[View](/en/documents/scientific-conclusion/briviact-h-c-psusa-00010447-202001-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Briviact-H-C-3898-P46-005 : EPAR - Assessment Report

Adopted

Reference Number: EMA/691193/2019

English (EN) (439.24 KB - PDF)

**First published:** 27/03/2020

[View](/en/documents/variation-report/briviact-h-c-3898-p46-005-epar-assessment-report_en.pdf)

Briviact-H-C-3898-P46-002 : EPAR - Assessment Report

Adopted

Reference Number: EMA/370511/2018

English (EN) (216.93 KB - PDF)

**First published:** 06/05/2019

[View](/en/documents/variation-report/briviact-h-c-3898-p46-002-epar-assessment-report_en.pdf)

Briviact-H-C-3898-II-0010-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/472006/2018

English (EN) (4.36 MB - PDF)

**First published:** 26/07/2018

**Last updated:** 26/07/2018

[View](/en/documents/variation-report/briviact-h-c-3898-ii-0010-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Briviact

Adopted

Reference Number: EMA/CHMP/327758/2018

English (EN) (61.17 KB - PDF)

**First published:** 01/06/2018

**Last updated:** 01/06/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-briviact_en.pdf)

Briviact-H-C-PSUSA-00010447-201607 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/266946/2017

English (EN) (61.76 KB - PDF)

**First published:** 28/04/2017

**Last updated:** 28/04/2017

[View](/en/documents/scientific-conclusion/briviact-h-c-psusa-00010447-201607-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Briviact : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/822086/2015

English (EN) (1.36 MB - PDF)

**First published:** 25/01/2016

**Last updated:** 25/01/2016

[View](/en/documents/assessment-report/briviact-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Briviact

Adopted

Reference Number: EMA/CHMP/742520/2015

English (EN) (67.38 KB - PDF)

**First published:** 20/11/2015

**Last updated:** 20/11/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-briviact_en.pdf)

#### News on Briviact (in Italy: Nubriveo)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022) 28/01/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-may-2018) 01/06/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 November 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-november-2015) 20/11/2015

#### More information on Briviact (in Italy: Nubriveo)

- [EMEA-000332-PIP01-08-M15 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000332-pip01-08-m15)
- [EMEA-000332-PIP01-08-M16 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000332-pip01-08-m16)
- [EMEA-000332-PIP02-17-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000332-pip02-17-m05)
- [Briviact (in Italy: Nubriveo) - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/briviact-italy-nubriveo)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 01/12/2025

## Share this page

[Back to top](#main-content)